T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

Now, although the funding environment looks different from the pandemic-era biotech bubble, conditions are ripening for the return of the IPO as a viable exit for private drugmakers, according to a ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...

According to MarketsandMarkets™, the Wearables in Pharma & Biotech Market is projected to grow from about USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%.

Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., ...

E22 guideline should incorporate caregiver feedback, according to responses submitted by industry groups and manufacturers to ...